Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...

Headquartered in New Brunswick, Johnson & Johnson (JNJ) is a Medical stock that has seen a price change of 0.45% so far this year. The world's biggest maker of health care products is currently ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a price target of $175.00. The company’s shares closed ...

Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other stocks Jim Cramer recently discussed. In his latest appearance on CNBC’s Squawk on the ...

Analysts cite Stelara exclusivity loss and MedTech competition as key challenges for Johnson & Johnson. Price target revisions: Tim Anderson lowers J&J forecast from $160 to $159. Get Wall Street ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best cheap stocks to buy for 2025. The U.S. consumer prices report released this week ...

Deep-pocketed investors have adopted a bearish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Johnson & Johnson has underperformed its large-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Even though JNJ has displayed an improving track record of beating ...

Overall, Johnson & Johnson had a strong quarter, continuing to expand its product pipeline and positioning itself well amid market fluctuations. Johnson & Johnson is a diversified healthcare giant ...

Gabby Jones / Bloomberg / Getty Images Johnson & Johnson is scheduled to report fourth-quarter earnings Wednesday morning, with analysts expecting sales and profits to grow year-over-year.